Process Development: Replicating The Final Cell Therapy Product
Access to leukopaks from patients with the same autoimmune conditions the therapy programs aim to treat enables the process development team to achieve more accurate analytical data related to manufacturing quality...
Isolating Rare Cell Types From Peripheral Blood
According to the investigator, the disease-state leukopak from Sanguine “represents a unique biospecimen type that solves a major issue for us– procuring an adequate number of cells from disease-state donors...
How Decentralizing the Manufacturing of Cell and Gene Therapies Benefits Patients
Decentralizing the manufacturing of cell and gene therapies has the potential to revolutionize the way we treat a wide range of diseases, from cancer to rare genetic disorders. Currently...
Cell & Gene Therapy Issue of Sanguine Specimen
Sanguine now offers healthy leukopaks, in addition to disease-state apheresis products covering 35+ conditions, directly from our diverse network of research-ready study participants.
The BACH1 inhibitor ASP8731 inhibits inflammation and vaso-occlusion and induces fetal hemoglobin in sickle cell disease
Belcher, Nataraja, Abdulla et al Front Med (Lausanne) (2023) 10, 1101501 DOI: 10.3389/fmed.2023.1101501